Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design.
Jardine, J.G., Sok, D., Julien, J.P., Briney, B., Sarkar, A., Liang, C.H., Scherer, E.A., Henry Dunand, C.J., Adachi, Y., Diwanji, D., Hsueh, J., Jones, M., Kalyuzhniy, O., Kubitz, M., Spencer, S., Pauthner, M., Saye-Francisco, K.L., Sesterhenn, F., Wilson, P.C., Galloway, D.M., Stanfield, R.L., Wilson, I.A., Burton, D.R., Schief, W.R.(2016) PLoS Pathog 12: e1005815-e1005815
- PubMed: 27560183 
- DOI: 10.1371/journal.ppat.1005815
- Primary Citation of Related Structures:  
5D9Q, 5KZC - PubMed Abstract: 
An optimal HIV vaccine should induce broadly neutralizing antibodies (bnAbs) that neutralize diverse viral strains and subtypes. However, potent bnAbs develop in only a small fraction of HIV-infected individuals, all contain rare features such as extensive mutation, insertions, deletions, and/or long complementarity-determining regions, and some are polyreactive, casting doubt on whether bnAbs to HIV can be reliably induced by vaccination ...